April 15, 2014 09:51 ET
CALGARY, ALBERTA--(Marketwired - April 15, 2014) - Supreme Pharmaceuticals Inc. (the "Company") (OTCBB:SPRWF)(TSX VENTURE:SL) reports that the parties to the agreement to acquire the South Okanagan producing medical marijuana facility, have mutually agreed upon an extension of the due diligence period to April 29th, 2014.
In addition, the Company has cancelled its plans for the previously announced private placement.
SUPREME PHARMACEUTICALS INC.
David Stadnyk, President & CEO
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD LOOKING INFORMATION
This News Release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com. This News Release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Supreme Pharmaceuticals Inc.David StadnykPresident & CEO(647) email@example.com
See all RSS Newsfeeds